REG - Nuformix PLC - Notice of AGM

NuformixAnnouncement

31/07/2023 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230731:nRSe7165Ha&default-theme=true

RNS Number : 7165H  Nuformix PLC  31 July 2023

Nuformix plc

("Nuformix" or the "Company" or the "Group")

 

Notice of Annual General Meeting ("AGM")

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces that
the 2023 Notice of AGM has today been posted to its shareholders:

 

A full pdf version of the Notice of AGM will shortly be available for download
from the Investor Information section on the Company's website
www.nuformix.com (http://www.nuformix.com) .

 

The AGM will be held on 24 August 2023 at 10.00 am at the offices of
Shakespeare Martineau, 6(th) floor, 60 Gracechurch Street, London, EC3V 0HR.

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director                Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes / Bob Pountney (Corporate Broking)     +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of pre-clinical assets with potential
for significant value and early licensing opportunities.

 

 

For more information, please visit www.nuformix.com
(http://www.nuformix.com/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOADFLBXXDLLBBD